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Abstract: Chalcone derivatives have attracted increasing attention due to their numerous 
pharmacological activities. Changes in their structures have displayed high degree of 
diversity that has proven to result in a broad spectrum of biological activities. The present 
study highlights the synthesis of some halogen substituted chalcones 3(a–i) containing the 
5-chlorothiophene moiety, their X-ray crystal structures and the evaluation of possible 
biological activities such as antibacterial, antifungal and reducing power abilities. The 
results indicate the tested compounds show a varied range of inhibition values against all 
the tested microbial strains. Compound 3c with a p-fluoro substituent on the phenyl ring 
exhibits elevated antimicrobial activity, whereas the compounds 3e and 3f displayed the 
least antimicrobial activities. The compounds 3d, 3e, 3f and 3i showed good ferric and 
cupric reducing abilities, and the compounds 3b and 3c showed the weakest reducing 
power in the series. 
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1. Introduction 
Chalcones are important constituents of many natural products. They are abundant in edible plants 
where they are considered to be the precursors of flavonoids and isoflavonoids. There is growing 
interest in the pharmacological potential of chalcones which constitute an important group of natural 
and synthetic products that have been screened for a wide range of pharmacological activities such  
as antibacterial [1,2], antitumor [3–5], anti-inflammatory [6–9], antifungal [10] and antioxidant 
properties [11–15]. Chalcones are also well known intermediates for synthesizing various heterocyclic 
compounds. Several methods have been reported for the synthesis of chalcones, among them aldol 
condensation and Claisen-Schmidt condensation between aryl ketones and aromatic aldehydes in acidic 
or basic media still occupy prominent positions. Chalcones are characterized by possessing an enone 
moiety between two aromatic rings. Elemental sulfur has been well known to act as an antifungal agent 
for a long time. Several naturally occurring antifungal agents are also known to contain sulfur [16]. 
Many researchers have reported chalcones containing sulfur either as a part of heteroaryl ring 
(thiophene) or as a side chain (thiomethyl group). Tomar et al. have reported the synthesis and 
antimicrobial activity of chalcones containing the 2,5-dichlorothiophene moiety [17]. Seema et al. 
have reported the synthesis and biological evaluation of α,β-unsaturated ketones as potential antifungal 
agents [18]. Tran et al. have reported the synthesis and antibacterial activity of some heterocyclic 
chalcone analogues alone and in combination with antibiotics [19]. Ranganathan et al. have reported 
the synthesis and antimicrobial studies of some of the 5-chloro-2-acetylthiophene chalcones [20]. In 
continuation of our research work on the X-ray crystal structure studies of 5-chlorothiophene chalcone 
analogues [21], in which an effort has been made to diversify the pharmacological activities by 
exploring the structural diversity of conventional chalcones, a series of halogen(s)-substituted chalcone 
analogues containing electron-rich thiophene heterocycles were synthesized. This was done with the 
expectation that the derivatives with halogen functionalities at different positions on the phenyl ring 
would be even more potent as antimicrobial agents than the starting compounds. Herein we report the 
synthesis of some novel halogen substituted chalcone analogues with 5-chlorothiophene moiety using 
the conventional base-catalyzed Claisen-Schmidt condensation, their crystal structures and the 
evaluation of their antimicrobial, ferric ion and cupric ion reducing power abilities. 
2. Results and Discussion 
Chalcones, a versatile class of natural and synthetic compounds, have attracted the interest of 
researchers for their wide range of biological activities. Chalcones containing the thiophene moiety are 
supposed to further enhance these activities. The best known method for the synthesis of chalcones is 
the Claisen-Schmidt condensation between acetophenone and benzaldehyde in basic media. New 
chalcones have been designed and synthesized by the reaction of 2-acetyl-5-chlorothiophene with 
halogen-substituted benzaldehydes using a catalytic amount of NaOH in methanol as shown in Scheme 1. Molecules 2013, 18   12709 
 
Scheme 1. Synthesis of heterocyclic chalcone analogues. 
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3a: R1 = F, R2, R3, R4 & R5 = H
3b: R2 = F, R1, R3, R4 & R5 = H
3c: R3 = F, R1, R2, R4 & R5 = H
3d: R2 = Cl, R3 = F, R1, R4 & R5 = H
3e: R2 = Br, R3 = F, R1, R4 & R5 = H
3f: R1 = F, R3 = Br, R2, R4 & R5 = H
3g: R2 = Cl, R1, R3, R4 & R5 = H
3h: R2 & R4 = Cl, R1, R3 & R5 = H
3i: R1 & R5 = Cl, R2, R3 & R4 = H
 
2.1. X-Ray Crystal Structure Description for Compounds 3a–3i 
The crystal structures of 3(a–i) are as shown in Figure 1. Table 1 lists the crystallographic data for 
all the nine compounds. Four out of nine compounds were crystallized in orthorhombic system, where 
3a in space group Pca21, 3c, 3d and 3e in space group Pbca. The remaining compounds (3b, 3f, 3g, 3h 
and 3i) crystallized in monoclinic system with space group P21/c. The overall conformation of the 
molecules (3a–i) can be described by the dihedral angles formed between the thiophene   
(S1/C1—C4) and the benzene (C8—C13) rings. The respective parameters are listed in Table 2. As 
seen from the table, the conformation of the molecules is almost planar except for compound 3i and it 
can be related to the presence of substituent in the -ortho position of the benzene ring. Compound 3i 
contains two crystallographically independent molecules (molecules A & B). The thiophene and 
benzene rings in compounds 3i are relatively far from planarity as the values of dihedral angles 
between them are 45.68 (11)° in molecule A and 24.00 (11)° in molecule B. The overlay of both 
molecules over all atoms is shown in Figure 2, with the r.m.s value of 0.339 Å. 
Compounds 3a, 3b and 3c differ structurally from each other by having the fluoro-substituent at  
-ortho, -meta and -para positions of the benzene rings, respectively. The planarity of the molecules are 
indicated by the dihedral angles as shown in Table 2, ranging from 5.5 (2) to 15.1 (3)°. Figure 3 shows 
the overlaid molecules over all the non-H atoms, calculated using the chlorothiophene moiety with the 
r.m.s values of 0.103 Å for 3a/3b and 3a/3c, and 0.051 Å for 3b/3c. There is no classical hydrogen 
bond found in compounds 3a and 3b. The formation of short intra-molecular S···O contacts of 2.926(3) 
and 2.933(4) Å which is 0.39 Å shorter than the sum of van der Waals radii of the sulfur and oxygen 
atoms, in both 3a and 3b, could be due to the charge delocalization into the carbonyl group from the 
thiophene ring. This helps to stabilize the molecular structure. In the crystal structure   
(Figure 4a), molecules in 3a are stacked along the b-axis, with alternative stacks forming an inverted 
head-to-tail arrangement. In 3b, the molecules stacked on each other in an inverse fashion along the  
b-axis (Figure 4b), whereas in compound 3c, the molecules are linked into chains along b-axis as Molecules 2013, 18   12710 
 
illustrated in Figure 5, via intermolecular C3—H3A···O1 and C9—H9A···O1 hydrogen bonds (Table 3), 
forming  ) 10 (
1
2 R ring motifs [22]. 
Figure 1. (a)–(i). Ortep diagram of compounds 3a to 3i (3h and 3i are drawn at 50% 
ellipsoids for non-hydrogen atoms and the remaining compounds are drawn at 30% 
ellipsoids for non-hydrogen atoms). 
 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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Table 1. Crystal data and parameters for structure refinement of 3a to 3i. 
Compound 3a  3b  3c  3d  3e  3f 3g 3h  3i 
CCDC deposition 
number 
939875 939876  939877  942741 942742 948856   944072  946445   948855  
Molecular formula  C13H8ClFOS C13H8ClFOS C13H8ClFOS C13H7Cl2FOS C14H7BrClFOS  C13H7BrClFOS C13H8Cl2OS C13H7Cl3OS C13H7Cl3OS 
Molecular weight  266.70  266.70  266.70  301.15  345.61  345.61 283.15 317.60  317.60 
Crystal system  Orthorhombic  Monoclinic  Orthorhombic Orthorhombic  Orthorhombic  Monoclinic Monoclinic Monoclinic  Monoclinic 
Space group  Pca21  P21/c  Pbca Pbca  Pbca  P21/c  P21/c  P21/c  P21/c 
a (Å)  27.963(9)  14.282(6)  7.9809(8)  7.4870 (9)  7.476 (2)  3.8704 (7)  14.5437 (10)  14.9864(10)  30.3418 (16) 
b (Å)  3.9233(15)  7.698(4)  11.0207(11)  11.6186 (14)  11.724 (3)  31.953 (6)  7.5227(6)  3.8085(3)  3.7985 (2) 
c (Å)  11.146(4)  11.376(5)  27.518(3)  29.239 (4)  30.009 (8)  10.273 (2)  11.7604(9)  24.6297(13)  23.4311 (12) 
α (°)  90  90  90  90  90  90 90 90  90 
β (°)  90  104.430  90  90  90  95.243 (3)  104.721 (1)  115.264(3)  109.297 (1) 
γ (°)  90  90  90  90  90  90 90 90  90 
V (Å
3)  1222.8(7)  1211.3(9)  2420.3(4)  2543.4 (5)  2630.4 (13)  1265.2 (4)  1244.44(16)  1271.30(15)  2548.8 (2) 
Z  4 4  8  8 8 4 4 4  8 
Dcalc (g cm
−3) 1.449  1.462  1.464  1.573  1.745  1.814 1.511 1.659  1.655 
Crystal dimensions  
(mm) 
0.93 × 0.18 × 0.05  0.25 × 0.25 × 0.05  0.79 × 0.37 × 0.04  0.75 × 0.52 × 0.10  0.58 × 0.28 × 0.09  0.89 × 0.12 × 0.09  0.50 × 0.23 × 0.08  0.51 × 0.10 × 0.05  0.60 × 0.10 × 0.10 
Colour Colourless  Colourless  Colourless Colourless  Colourless  Colourless Colourless Colourless  Colourless 
μ(mm
−1) 0.47  0.48  0.48  0.67  3.48  3.62 0.67 0.87  0.86 
Radiation λ (Å)  0.71073  0.71073  0.71073  0.71073  0.71073  0.71073 0.71073 0.71073  0.71073 
Tmin/Tmax 0.668/0.975  0.889/0.975  0.704/0.980  0.633/0.935  0.237/0.752  0.141/0.744 0.733/0.946 0.665/0.955  0.624/0.922 
Reflections measured  8618  9071  24679  16026  16116  2855 11650 11375 20108 
Ranges/indices  
(h, k, l) 
−37, 39; −5, 5; 
−15, 15 
−16, 16; −9, 9; 
−13, 13 
−11, 11; −15, 15; 
−38, 37 
−10, 10; −14, 16; 
−41, 37 
−10, 9; −12, 16; 
−42, 31 
−5, 5; −41, 41; −1, 
13 
−18, 18; −9, 9; 
−15, 15 
−19, 19; −4, 4; 
−31, 31 
−39, 39; −4, 4; 
−30, 30 
θ limit (°)  2.3–22.4  3.0–19.5  3.2–25.3  2.8–26.4  2.7–25.3  2.8–29.8 2.9–29.0 2.8–30.1  2.9–29.9 
Unique reflections  3368  2126  3540  3738  3816  2855 2829 2894  5762 
Observed reflections  
(I > 2σ(I)) 
1899 1133  2016  2486 1935 2624 2312 2607  4784 
Parameters 154  154  154  163  163  164 154 163  325 
Goodness of fit on F
2 0.99  1.00  1.03  1.03  1.01  1.09 1.04 1.05  1.03 
R1, wR2 [I ≥ 2σ(I)]  0.049, 0.136  0.059, 0.191  0.047, 0.135  0.041, 0.135  0.044, 0.136  0.051, 0.127  0.030, 0.101  0.046, 0.120  0.033, 0.091 
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Table 2. The dihedral angles formed between the chlorothiophene and benzene rings. 
Compound  Dihedral angle between two rings (°) 
3a  5.5 (2) 
3b  15.1 (3) 
3c  14.98 (13) 
3d  9.45 (9) 
3e  6.58 (16) 
3f  1.2 (2) 
3g  16.40 (8) 
3h  2.07 (15) 
3i 
Molecule A-45.68 (11) 
Molecule B-24.00 (11) 
Figure 2. Overlay of molecules A and B in compound 3i, calculated using the 
chlorothiophene moiety. 
 
Table 3. Hydrogen bond geometries for the compounds 3c, 3f, 3h and 3i. 
D–H···A d(D–H) (Å) d (H···A)(Å) d (D···A)(Å) Angle(D–H···A)(°) 
3c       
C3—H3A···O1 
i 0.93  2.56 3.438(3)  157 
C9—H9A···O1 
i 0.93  2.54 3.474(3)  179 
3f       
C2—H2A···F1 
ii 0.95  2.40 3.295  (5)  156 
C3—H3A···O1 
ii 0.95  2.48 3.381  (5)  158 
3h       
C7—H7A···O1 
iii 0.93  2.49 3.337(4)  151 
C13—H13A···O1 
iii 0.93  2.48  3.300(4)  148 
3i       
C2B—H2BA···O1A 
iv 0.95  2.50  3.209(3)  131 
Symmetry code: (i) −x+1/2, y−1/2, z; (ii) x−1, −y+1/2, z−1/2; (iii) −x+1, −y+2, −z; (iv)x, −y+5/2, z+1/2. Molecules 2013, 18 12713 
 
Figure 3. Overlay of all non-H atoms in compounds 3a, 3b and 3c, calculated using the 
chlorothiophene moiety. 
 
Figure 4. Crystal structures of (a) 3a and (b) 3b. The molecules are stacked along the b-axis. 
 
(a) (b) 
Figure 5. Crystal structure of 3c forming chains along the b-axis. Dashed lines indicate the 
intermolecular hydrogen bonds. 
 
Compounds 3d, 3e and 3f differ from 3a–3c by the additional halogen substituent at the benzene 
rings. The chlorothiophene and the benzene rings of 3d–3f are approximately planar, with dihedral 
angles ranging from 1.2 (2) to 9.45 (9)°. The conformations of these three molecules are very 
analogous as indicated by the overlay, excluding H atoms and the halogen substituents on the benzene 
rings (Figure 6) with r.m.s values of 0.033 Å for 3d/3e, 0.111 Å for 3d/3e and 0.088 Å for 3e/3f. Molecules 2013, 18 12714 
 
Compounds 3d and 3e were observed to possess no significant hydrogen bonds. They are stabilized by 
the formation of short intramolecular S···O contacts of 2.933 (4) and 2.929 (3) Å, respectively, which 
is 0.39 Å shorter than the sum of van der Waals radii of the sulfur and oxygen atoms. In the crystal 
structure, molecules in 3d and 3e stacked along the a-axis, as depicted in Figure 7a,b, respectively. In 
the crystal packing of 3f (Figure 8), intermolecular C2—H2A···F1 and C3—H3A···O1 hydrogen bonds 
(Table 3) link the molecules into chains along the c-axis, generating ) 11 (
2
2 R ring motifs [22]. 
Figure 6. Overlay of compounds 3d, 3e and 3f excluding halogen substituents at benzene 
rings and H-atoms. 
 
Figure 7. Crystal structures of (a) 3d and (b) 3e, showing the stacking along the a-axis. 
(a) (b) 
Figure 8. Crystal structure of 3f, showing the chains along the c-axis. Dashed lines 
indicate the intermolecular hydrogen bonds.  
    Molecules 2013, 18 12715 
 
Compounds 3g, 3h and 3i present one or two chloro-substituents at the benzene rings. Compounds 
3g and 3h are approximately planar as indicated in Table 2. Figure 9a,b show the overlays of all non-H 
atoms of 3g/3h,  3g/3i and 3h/3i, calculated using the chlorothiophene moiety excluding their   
chloro-substituents. The r.m.s values given by the overlays of 3g/3h, 3g/3i (molecule A) and 3h/3i 
(molecule A) are 0.167, 0.323 and 0.447 Å, respectively. These values are compared with another 
overlay (Figure 9b), taking only molecule B into the calculation and the r.m.s values given by the 
overlays of 3g/3i (molecule B) and 3h/3i (molecule B) are 0.205 and 0.248 Å, respectively. In general, 
due to intermolecular hydrogen bonding of molecules A and B in compound 3i, they are very much 
deviated from the molecules of compounds 3g and 3h. Crystal packing diagram of 3g with no 
significant hydrogen bonds is depicted in Figure 10a. However, the molecules in 3g are stabilized by 
the short intra-molecular S···O contacts of 2.9348(14) Å, which is 0.39 Å shorter than the sum of van 
der Waals radii of the sulfur and oxygen atoms. The molecules in compound 3h (Figure 10b) are linked 
to form dimers with ) 10 (
2
2 R ring motifs [22] via intermolecular C7—H7A···O1 hydrogen bonds (Table 3). 
These sets of dimers are further connected by intermolecular C13—H13A···O1 hydrogen bonds (Table 
3) into another two ) 6 (
1
2 R ring motifs. The molecules stacked along the b-axis. In the crystal structure of 
3i (Figure 11), molecules A highlighted in green are joined with the adjacent molecules B highlighted 
in blue through intermolecular C2B—H2BA···O1A hydrogen bonds (Table 3). 
Figure 9. Overlay of compounds 3g, 3h and (a) 3i with only molecule A and (b) 3i with 
only molecule B where their chloro-substituents were excluded. 
(a) (b) 
Figure 10. Crystal structures of (a) 3g viewed along the c-axis (b) 3h viewed along the  
b-axis. Dashed lines indicate the intermolecular hydrogen bonds. 
(a) (b) Molecules 2013, 18 12716 
 
Figure 11. Crystal packing of 3i, viewed along the b-axis. Dashed lines indicate the 
intermolecular hydrogen bonds. 
 
2.2. In Vitro Antimicrobial Activity 
The synthesized compounds 3(a–i) were evaluated for their in vitro antibacterial activity and the 
results are compared with bacteriomycin and gentamycin used as standard drugs (Figure 12). All the 
tested compounds displayed varied antibacterial activity against four pathogenic bacterial strains: 
Bacillus subtilis MTCC 121, Staphylococcus aureus MTCC, Xanthomonas campestris MTCC 7908 
and  Escherichia coli MTCC 7410. Among the series 3(a–i), compound 3c showed an elevated 
antibacterial activity against the tested bacterial strains and the compounds 3a, 3b and 3g showed good 
antibacterial activity against all the tested organisms. The compounds 3d,  3h and 3i displayed 
moderate activity, while the compounds 3e and 3f showed the least inhibitory activity in the series. 
Further, all the synthesized compounds 3(a–i) were evaluated for their in vitro antifungal activity 
against Fusarium oxysporum. The results are shown and compared with the standard drug nystatin  
in Figure 13. Compounds 3a, 3b and 3c showed good antifungal activity against F. oxysporum when 
compared to other compounds in the series. Compounds 3d, 3g, 3h and 3i were found to be moderately 
active against the tested fungal strain. The compounds 3e and 3f were less active. 
A close survey of the antimicrobial results indicates the compounds under test show a varied range 
of inhibition values against all the tested bacterial and fungal strains. The elevated activity of the 
compound 3c may be due to the p-fluoro substituent on the phenyl ring. Moreover the good activity of 
compounds  3a,  3b and 3g can be attributed to the o-fluoro,  m-fluoro and m-chloro substitution, 
respectively. The least activity of compounds 3e and 3f against the tested fungal strain may be due to 
the presence of bromo substituents. An increase in the number of halogen substituents on the phenyl 
ring results in a decrease in the antimicrobial activity of the tested compounds. The activities of the 
reported compounds against the tested bacterial strains were in the order 3c > 3a > 3b > 3g > 3h > 3i > 
3d > 3e > 3f. Molecules 2013, 18 12717 
 
Figure 12. In vitro antibacterial activities of 3(a–i). 
 
Figure 13. In vitro antifungal activity of 3(a–i). 
 
2.3. Reducing Power Ability 
The synthesized compounds were further tested for their reducing power ability. Ferric ion reducing 
antioxidant power (FRAP) assay and cupric ion reducing antioxidant capacity (CUPRAC) were 
measured using butylated hydroxytoluene as the standard. 
2.3.1. Ferric Reducing Antioxidant Power (FRAP) Assay 
In practice, the antioxidant activity of a substance is directly correlated to its reducing ability. 
Standard assays like FRAP provide a reliable method to verify the antioxidant ability of a substance. 
Substances having reduction potential react with potassium ferricyanide forming potassium 
ferrocyanide. The formed potassium ferrocyanide further reacts with FeCl3 to form an intense Prussian 
blue complex which has a maximum absorbance at 700 nm. The complex formed is directly 
proportional to the reducing capacity of the test sample. An increase in absorbance is equal to the 
reducing power of the sample. Results are depicted in Figure 14 and from the analysis it is clear that Molecules 2013, 18 12718 
 
the compounds 3d, 3e, 3f and 3i showed good ferric reducing ability, whereas 3a, 3g and 3h were 
moderate, and the compounds 3b and 3c showed the least reducing ability among the series. 
Figure 14. Ferric ion reducing power ability of samples 3(a–i) at different concentration 
(10–50 μg/mL) measured at 700 nm. Values are expressed as absorbance; high absorbance 
indicates high reducing power. 
 
2.3.2. Cupric Ion Reducing Antioxidant Capacity (CUPRAC) Assay 
In this assay a sample under evaluation effectively reduces Cu
2+ to Cu
+, changing the characteristic 
ion absorption. The reduced Cu
+ ion combines with the chromogenic reagent neocuproine forming a 
stable 2:1 complex which has a maximum absorption at 450 nm. This method operates at pH 7. 
Results, shown in Figure 15, indicate that the majority of these test compounds have good reducing 
ability. These compounds displayed 40% less reducing power compared to the standard. Compounds 
3d,  3e,  3f and 3i showed good cupric reducing ability, whereas compounds 3a,  3g and 3h were 
moderate, and the compounds 3b and 3c showed the least reducing ability among the series. 
Figure 15. Cupric ion reducing power ability of samples 3(a–i) at different concentration 
(10–50 μg/mL) measured at 700 nm. Values are expressed as absorbance; high absorbance 
indicates high reducing power. 
 Molecules 2013, 18 12719 
 
3. Experimental 
3.1. Materials and Method 
Melting points were determined on a Stuart Scientific (UK) apparatus. The purity of each 
compound was confirmed by thin layer chromatography using Merck silica gel 60 F254-coated 
aluminium plates. The mass spectra were recorded on a Jeol JMS-D 300 mass spectrometer operating 
at 70 eV. Elemental analyses (CHN) were carried out on a Perkin Elmer Series II, 2400 analyzer.  
X-ray analysis was done using a Bruker SMART Apex II or Apex II Duo CCDC diffractometer. The 
data were processed with SAINT and absorption correction was done using SADABS [23]. The 
structures were solved by direct method using the program SHELXTL [24], and were refined by   
full-matrix least squares technique on F
2  using anisotropic displacement parameters. The   
non-hydrogen atoms were refined anisotropically. In these compounds, all the H atoms were calculated 
geometrically with isotropic displacement parameters set to 1.2 (1.5 for methyl groups) times the 
equivalent isotropic U values of the parent carbon atoms. The overlay structures were drawn using 
Olex
2 software [25]. Crystallographic data for compounds 3(a–i) have been deposited at the 
Cambridge Crystallographic Data Centre with CCDC No: 939875, 939876, 939877, 942741, 942742, 
948856, 944072, 946445 and 948855, respectively. Copies of the data can be obtained free of charge 
on application to the CCDC, 12 Union Road, Cambridge CB2 IEZ, UK. Fax: +44-(0)1223-336033 or 
E-Mail: deposit@ccdc.cam.ac.uk. 
3.2. General Procedure for the Synthesis of Chalcones 3(a–i) 
A mixture of 2-acetyl-5-chlorothiophene (0.01 mol) and a halogen-substituted benzaldehyde (0.01 mol) 
was dissolved in methanol (20 mL). Catalytic amount of NaOH was added to the solution drop-wise 
with vigorous stirring. The reaction mixture was stirred for about 5–6 h at room temperature. The 
resultant crude products were filtered, washed successively with distilled water and recrystallized from 
ethanol to get corresponding chalcones. Crystals suitable for X-ray diffraction studies were obtained 
by the slow evaporation technique using a suitable solvent. 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(2-fluorophenyl)prop-2-en-1-one (3a): Solvent for growing crystals: 
Mixture of acetone and ethanol (1:1 v/v); Yield: 64%; M.P. 112–114 °C; LCMS: m/z = 267 (M
++1); 
Elemental analysis: Calculated for C13H8ClFOS: C, 58.54%; H, 3.02%; Found: C, 58.51%; H, 3.11%. 
CCDC No.: 939875. 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(3-fluorophenyl)prop-2-en-1-one (3b): Solvent for growing crystals: 
Mixture of acetone and ethanol (1:1 v/v); Yield: 61%; M.P. 118–120 °C; LCMS: m/z = 267 (M
++1); 
Elemental analysis: Calculated for C13H8ClFOS: C, 58.54%; H, 3.02%; Found: C, 58.49%; H, 3.17%. 
CCDC No.: 939876. 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(4-fluorophenyl)prop-2-en-1-one (3c): Solvent for growing crystals: 
Mixture of acetone and ethanol (1:1 v/v); Yield: 68%; M.P. 128–130 °C; LCMS: m/z = 267 (M
++1); 
Elemental analysis: Calculated for C13H8ClFOS: C, 58.54%; H, 3.02%; Found: C, 58.51%; H, 3.13%. 
CCDC No.: 939877. Molecules 2013, 18 12720 
 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(3-chloro-4-fluorophenyl)prop-2-en-1-one (3d): Solvent for growing 
crystals: Mixture of acetone, ethanol and acetonitrile (1:1:1 v/v); Yield: 63%; M.P. 167–169 °C;   
LCMS: m/z = 302 (M
++1); Elemental analysis: Calculated for C13H7Cl2FOS: C, 51.85%; H, 2.34%; 
Found: C, 51.79%; H, 2.48%. CCDC No.: 942741. 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(3-bromo-4-fluorophenyl)prop-2-en-1-one (3e): Solvent for growing 
crystals: Mixture of acetone, ethanol and acetonitrile (1:1:1 v/v); Yield: 60%; M.P. 144–146 °C; 
LCMS: m/z = 346 (M
++1); Elemental analysis: Calculated for C12H7BrClFOS: C, 45.18%; H, 2.04%; 
Found: C, 45.13%; H, 2.11%. CCDC No.: 942742. 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(4-bromo-2-fluorophenyl)prop-2-en-1-one (3f): Solvent for growing 
crystals: N,N-dimethylformamide; Yield: 62%; M.P. 133–134 °C; LCMS: m/z = 346 (M
++1); 
Elemental analysis: Calculated for C12H7BrClFOS: C, 45.18%; H, 2.04%; Found: C, 45.15%; H, 
2.09%. CCDC No.: 948856. 
(2E)-3-(3-Chlorophenyl)-1-(5-chlorothiophen-2-yl)prop-2-en-1-one (3g): Solvent for growing crystals: 
Mixture of acetone and ethanol (1:1 v/v); Yield: 70%; M.P. 120–122 °C; LCMS: m/z = 284 (M
++1); 
Elemental analysis: Calculated for C13H8Cl2OS: C, 55.14%; H, 2.85%; Found: C, 55.11%; H, 2.92%. 
CCDC No.: 944072. 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(3,5-dichlorophenyl)prop-2-en-1-one ( 3h): Solvent for growing 
crystals: Mixture of acetone, ethanol and ethyl acetate (1:1:1 v/v); Yield: 67%; M.P. 129–131 °C; 
LCMS: m/z = 318 (M
++1); Elemental analysis: Calculated for C13H7Cl3OS: C, 49.16%; H, 2.22%; 
Found: C, 49.13%; H, 2.29%. CCDC No.: 946445. 
(2E)-1-(5-Chlorothiophen-2-yl)-3-(2,6-dichlorophenyl)prop-2-en-1-one ( 3i): Solvent for growing 
crystals: N,N-dimethylformamide; Yield: 64%; M.P. 170–172 °C; LCMS: m/z = 318 (M
++1); 
Elemental analysis: Calculated for C13H7Cl3OS: C, 49.16%; H, 2.22%; Found: C, 49.12%; H, 2.27%. 
CCDC No.: 948855. 
3.3. in Vitro Antimicrobial Activities 
3.3.1. Antibacterial Activity 
All the synthesized compounds were screened for their antibacterial activity against Gram-positive 
bacteria such as Bacillus subtilis MTCC 121 and Staphylococcus aureus MTCC 7443 and Gram-negative 
bacteria such as Xanthomonas campestris MTCC 7908 and Escherichia coli MTCC 7410 in DMF by 
disc diffusion method on nutrient agar medium [26]. Each Petri plate was filled with sterile medium 
(nutrient agar medium, 15 mL) uniformly and smeared with cultures of Gram-positive bacteria to 
which 50 µL (1 mg/mL: i.e., 50 µg/disc) of the test compounds was added. The treatments also include 
50 µL of DMF as negative control and bacteriomycin and gentamycin as positive control for comparisons. 
Three replicates were maintained for each treatment. The plates were incubated at 37 ± 2 °C for 24 h and 
the zone of inhibition was determined. Molecules 2013, 18 12721 
 
3.3.2. Antifungal Activity 
Antifungal activity of the synthesized compounds was screened against Fusarium oxysporum 
MTCC 2480 in DMF by the poisoned food technique [27]. Potato dextrose agar (PDA) medium was 
prepared; to each Petri plate PDA (15 mL) was added and allowed to solidify. A 5 mm disc of 7 day-old 
culture of the test fungi was placed at the center of the Petri plate and incubated at 26 °C for 7 days. 
After the incubation period, the percentage inhibition was measured and three replicates were 
maintained for each treatment. Nystatin was used as the standard. Synthesized compounds were tested 
at the dosage of 500 µL of the novel compounds/Petri plate, where the concentration was 0.1 mg/mL 
by poisoned food technique. 
3.3.3. Ferric Ion Reducing Antioxidant Power (FRAP) Assay 
The synthesized compounds were screened for ferric reducing power antioxidant ability by the 
method reported by Oyaizu [28]. The method is based on the reduction of ferric (Fe
3+) to ferrous 
(Fe
2+), which is accomplished in presence of antioxidants. Samples of 3(a–i) having a concentration of 
10–50 μg/mL were mixed with an equal volume of 0.2 M phosphate buffer (pH 6.6) and 1% potassium 
ferricyanide and the mixture were incubated for 20 min at 50 °C. The mixture was acidified with  
2.5 mL of 10% trichloroacetic acid and then centrifuged at 3,000 rpm for about 15 min. The upper 
supernatant liquid was diluted with distilled water and 0.1% ferric chloride was added. The absorbance 
was measured at 700 nm. The increase in absorbance is directly proportional to the reducing ability of 
the compound. The control was prepared as above without the sample. 
3.3.4. Cupric Ion Reducing Antioxidant Capacity (CUPRAC) Assay 
The synthesized compounds were also evaluated for their cupric ion reducing power by a reported 
method [29]. CUPRAC is a widely applicable method for evaluating the antioxidant properties of a 
substance. A mixture of CuCl2 (1 mL, 0.01 M) solution, ethanolic neocuproine (1 mL, 0.0075 M) and 
ammonium acetate (1 mL, 1 M) were dissolved and 1 mL of test samples (10–50 μg/mL) was added 
along with 0.1 mL of distilled water. The mixture was incubated for about 30 min and the absorbance 
was measured at 450 nm against the blank solution. Control is prepared as above without the sample. 
3.3.5. Statistical Analysis 
All the assay measurement were performed in triplicate (n = 3) and are expressed as mean of the 
three determinations. 
4. Conclusions 
Halogen-substituted chalcone derivatives 3(a–i) bearing the 5-chlorothiophene moiety were 
synthesized in good yield and the structures of these compounds were determined by single crystal  
X-ray diffraction analysis. The crystal structure diversities of these compounds and various 
interactions responsible for their crystal stability are described. In addition, in vitro antimicrobial and 
reducing power ability of these compounds are evaluated. The reported compounds produced a varied Molecules 2013, 18 12722 
 
range of inhibition results against the tested microbial strains, which is due to the presence of electron 
negative halogen(s) substituents at different positions on the phenyl ring. The antimicrobial activity of 
the tested compounds follows the order 3c > 3a > 3b > 3g > 3h > 3i > 3d > 3e > 3f. These compounds 
displayed about 40% less reducing ability for ferric and cupric ions when compared to the standards. 
The present study demonstrated the relationship of the halogen linkage on the aromatic ring to the 
biological activities exhibited by these compounds. 
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